Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $97.16M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 2.55M
Average 2.44M
STIM Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Neuronetics, Inc.NASDAQ: STIM
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital grows, but more slowly than its trailing trend
Q1 FY2026 other working capital of $2.97M (cash outflow) rose 68.2% year over year, behind the +259.6% change in trailing-twelve-month other working capital. Over 3 fiscal years it compounded at -5.3% a year.
Context
- Other working capital amounted to 3.5% of revenue in FY2025, down 2.2 pp from a year earlier.
- Other working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +68.2% toward the trailing-twelve-month pace of +259.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- 5.18M USD
- Year-over-year change
- +222.0%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.18M | +222.0% |
| FY2024 | 2024-12-31 | (4.25M) | +31.5% |
| FY2023 | 2023-12-31 | (6.2M) | -201.7% |
| FY2022 | 2022-12-31 | 6.1M | +1569.2% |
| FY2021 | 2021-12-31 | (415K) | — |
Other Working Capital vs competitors
How STIM compares with its peers on the latest reported figures
- Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +259.6% is the highest of 9, against a peer median of -63.8%.
- Other working capital amounts to 2.6% of revenue for STIM, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.25M USD | — | — | 8.1% | |
| LTM Mar 2026 | $4.88M USD | -62.6% | — | 6.3% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $4.3M USD | -82.2% | +231.3% | 1.0% |
| LTM Mar 2026 | $3.98M USD | +259.6% | -5.3% | 2.6% | |
| LTM Mar 2026 | $3.24M USD | -52.9% | -28.0% | 11.2% | |
| LTM Mar 2026 | $1.84M USD | -112.1% | -58.2% | 5.3% | |
| LTM Mar 2026 | $1.31M USD | +156.9% | — | 212.5% | |
| LTM Mar 2026 | $937K USD | -65.0% | +18.8% | 0.8% | |
| LTM Mar 2026 | $233.68K USD | +243.4% | — | 1.2% | |
| LTM Mar 2026 | €0 EUR | -100.0% | — | 0.0% | |
| Peer median (excluding STIM) | — | -63.8% | -4.6% | 5.3% | |
Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.19M) | (37.16M) | (30.19M) | (43.73M) | (39.14M) |
| Depreciation & Amortization | 1.06M | 1.65M | 2.01M | 2.07M | 3.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.87M | 8.75M | 7.32M | 5.6M | 6.85M |
| Change in Working Capital | (6.64M) | (5.12M) | (14.1M) | (6.81M) | 6.58M |
| Accounts Receivables | (3.05M) | (6.66M) | (8.83M) | (3.73M) | 3.54M |
| Inventory | (3.44M) | (2.59M) | (1.1M) | 3.15M | (395K) |
| Accounts Payables | 276K | (1.97M) | 2.03M | (1.99M) | (1.75M) |
| Other Working Capital | (415K) | 6.1M | (6.2M) | (4.25M) | 5.18M |
| Other Non-Cash Items | 918K | 1.14M | 2.93M | 11.86M | 1.87M |
| Operating Cash Flow | (27.98M) | (30.74M) | (32.04M) | (31M) | (20.37M) |
| Capital Expenditures | (2.35M) | (3.27M) | (2.37M) | (1.47M) | (801K) |
| Acquisitions (Net) | 0 | 0 | 0 | (2.55M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 324K | 0 | 0 | 0 | (31K) |
| Other Investing Activities | (7.81M) | 10M | 1.05M | 1.61M | 31K |
| Investing Cash Flow | (9.84M) | 6.73M | (1.32M) | (2.41M) | (801K) |
| Debt Repayment | 0 | 0 | 23.8M | (2.52M) | 9.62M |
| Common Stock Issued | 80.97M | 0 | 0 | 0 | 26.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.03M | 207K | (1.1M) | (4.29M) | (594K) |
| Financing Cash Flow | 83.01M | 207K | 22.7M | (6.81M) | 35.85M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 45.18M | (23.8M) | (10.66M) | (40.22M) | 14.68M |
| Free Cash Flow | (30.34M) | (34.01M) | (34.41M) | (32.46M) | (21.18M) |
Neuronetics, Inc.
NASDAQ:STIM
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.